Proven clinical success of CUBICIN 4 mg/kg once daily in complicated skin infections, including S. aureus (MRSA and MSSA), demonstrated in two Phase 3 clinical trials
* 95% CI for the difference in success rates (comparator – CUBICIN).
† Assigned to vancomycin (MRSA) or semisynthetic penicillin (MSSA) according to physicians' evaluations.
‡ Pooled results of 2 trials.
Adapted from Arbeit et al.
- In these Phase 3 trials, patients had complicated infections (wound infection, major abscess, and infected diabetic and nondiabetic ulcers) predominately due to S. aureus1
Low rates of clinical relapse observed in patients treated with CUBICIN 4 mg/kg once daily in complicated skin infection clinical trials
*95% CI for the difference in relapse (comparator – CUBICIN). Adapted from Arbeit et al.
1
Phase 3 Trials of CUBICIN in Complicated Skin Infections
Among patients achieving clinical success on IV therapy only, patients not requiring second week of therapy
IV=intravenous.
Arbeit RD, Maki D. Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin structure infections.
Clin Infect Dis. 200438.1673-1681.
Incidence of clinical success* by infecting pathogen in microbiologically evaluable† patients
* Clinical success was defined as cure or clinical improvement, based primarily on the investigator's assessment of clinical response at the Test of Cure (TOC) evaluation, conducted 6 to 20 days after the conclusion of therapy.
† Microbiologically evaluable patients were clinically evaluable and had a confirmed Gram-positive pathogen isolated at baseline.
‡ Vancomycin or semisynthetic penicillins.
§ As determined by central laboratory.
Reference: 1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis. 2004;38:1673-1681.
